AstraZeneca Debt to Equity Ratio 2006-2018 | AZN

Current and historical debt to equity ratio values for AstraZeneca (AZN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. AstraZeneca debt/equity for the three months ending September 30, 2018 was 1.36.
AstraZeneca Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $18.42B $13.54B 1.36
2018-06-30 $15.45B $14.27B 1.08
2018-03-31 $15.68B $14.57B 1.08
2017-12-31 $15.56B $16.64B 0.94
2017-09-30 $16.91B $15.45B 1.10
2017-06-30 $16.79B $15.41B 1.09
2017-03-31 $14.56B $14.78B 0.99
2016-12-31 $14.50B $16.67B 0.87
2016-09-30 $14.74B $14.91B 0.99
2016-06-30 $16.52B $15.39B 1.07
2016-03-31 $14.14B $16.64B 0.85
2015-12-31 $14.14B $18.51B 0.76
2015-09-30 $8.28B $17.37B 0.48
2015-06-30 $8.30B $18.30B 0.45
2015-03-31 $8.27B $16.96B 0.49
2014-12-31 $8.40B $19.65B 0.43
2014-09-30 $7.53B $20.47B 0.37
2014-06-30 $7.57B $22.05B 0.34
2014-03-31 $7.55B $21.48B 0.35
2013-12-31 $8.59B $23.25B 0.37
2013-09-30 $8.57B $23.45B 0.37
2013-06-30 $8.51B $23.41B 0.36
2013-03-31 $9.32B $22.49B 0.41
2012-12-31 $9.41B $23.95B 0.39
2012-09-30 $9.35B $22.26B 0.42
2012-06-30 $7.31B $22.23B 0.33
2012-03-31 $7.38B $21.72B 0.34
2011-12-31 $7.34B $23.47B 0.31
2011-09-30 $7.39B $24.15B 0.31
2011-06-30 $9.21B $23.82B 0.39
2011-03-31 $9.16B $22.55B 0.41
2010-12-31 $9.10B $23.41B 0.39
2010-09-30 $9.23B $22.31B 0.41
2010-06-30 $9.04B $22.27B 0.41
2010-03-31 $9.06B $20.89B 0.43
2009-12-31 $9.14B $20.82B 0.44
2009-09-30 $10.29B $19.55B 0.53
2009-06-30 $10.16B $17.94B 0.57
2009-03-31 $10.01B $15.53B 0.64
2008-12-31 $10.86B $16.06B 0.68
2008-09-30 $10.83B $16.11B 0.67
2008-06-30 $11.03B $15.97B 0.69
2008-03-31 $11.12B $14.72B 0.76
2007-12-31 $10.88B $14.78B 0.74
2007-09-30 $0.00B $0.00B 0.00
2007-06-30 $1.06B $14.85B 0.07
2007-03-31 $1.09B $13.91B 0.08
2006-12-31 $1.09B $15.30B 0.07
2006-09-30 $1.09B $14.68B 0.07
2006-06-30 $1.05B $14.91B 0.07
2006-03-31 $1.08B $13.62B 0.08
2005-12-31 $1.11B $13.60B 0.08
2005-09-30 $1.12B $13.28B 0.09
2005-06-30 $1.16B $13.48B 0.09
2005-03-31 $1.07B $13.59B 0.08
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $97.922B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $393.045B 18.43
Pfizer (PFE) United States $261.986B 14.77
Merck (MRK) United States $207.903B 18.02
Novartis AG (NVS) Switzerland $201.478B 17.27
AbbVie (ABBV) United States $132.627B 11.77
Eli Lilly (LLY) United States $121.292B 21.32
Sanofi (SNY) France $111.158B 13.76
Novo Nordisk (NVO) Denmark $110.447B 17.94
GlaxoSmithKline (GSK) United Kingdom $92.650B 12.45
Bristol-Myers Squibb (BMY) United States $85.576B 14.09